Medical Treatment & Drug Development
Mécénat des Mutuelles
France
New Molecule to Combat Antibiotic-Resistant Childhood Sepsis
Antibiotic resistance is a major public health issue. According to the WHO, 5 million people die each year worldwide because of antibiotic resistance. By 2050, antibiotic-resistant infections could become the leading cause of death worldwide, with 10 million cases per year if no action is taken. Thus, the identification and characterization of new molecules targeting innovative bacterial targets and original mechanisms of action is urgent, particularly with regard to the main pathogens involved in sepsis. Sepsis is a generalized inflammatory response to a serious infection resulting in loss of organ function and a life-threatening risk to the patient. Neonatal sepsis is the 3rd leading cause of neonatal death in the world with 350,000 deaths per year, 2/3 of which are due to resistant bacteria.
The global spread of antibiotic resistance requires the identification of new bacterial drug targets, the design and synthesis of innovative anti-infectives.
To address the issue, Nalini Rama Rao's project proposes the development of innovative molecules effective in the fight against antibiotic resistance through the inhibition of a new bacterial target by new therapeutic molecules.
Her team have has identified and characterized a drug candidate and demonstrated its efficacy against a broad spectrum of bacteria, including pathogenic bacteria resistant to current treatments. Its safety for the host and its microbiota has also been shown.
In the medium and long term, this project should provide industry with new compounds to be developed and the healthcare system with new therapeutic possibilities in the face of the uncontrolled rise of antibiotic resistance. Indeed, the development of new molecules targeting a universal factor of resistance to the immune response will make it possible to propose innovative alternatives to fight sepsis for better patient care and a reduced societal cost.
Tran et al Nature Communication 2025 https://doi.org/10.1038/s41467-025-58282-8
https://propagaction.mozello.shop/
Nalini
RAMA RAO
Institution
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Country
France
Nationality
French
Related articles
Chronic & Non-communicable Diseases
Medical Treatment & Drug Development
AXA Project
France
Pain Pediatric & Elderly AXA Research Lab (PEARL)
Cutaneous neuropathic pain is a highly debilitating chronic condition, characterized by persistent sensations of burning, tingling, or hypersensitivity. It disproportionately... Read more
Celine
GRECO
Hôpital Necker-Enfants Malades
Medical Treatment & Drug Development
Mécénat des Mutuelle
France
Accelerating drug innovation with the Euridis school and its DDD Challenge
The project addresses a dual challenge: on one hand, the increasing complexity of drug development, which requires a thorough understanding... Read more
Laurence
SABATIER
Institut du médicament de Strasbourg
Medical Treatment & Drug Development
Post-Doctoral Fellowship
Germany
Fighting bacterial infection by targeting the ability of pathogens to hijack the body's defense system
Towards developing a new generation of antibiotics that target bacterial ubiquitin ligases used to hijack the host cells Dr. Timurs... Read more
Timurs
MACULINS